Evidence map›Paper›PMID 29845408›Full record

ReviewMedical oncology (Northwood, London, England)2018

Is there a role for immunotherapy in malignant pleural mesothelioma?

Alfredo Tartarone, Rosa Lerose, Michele Aieta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Immunotherapy for advanced and recurrent malignant pleural mesothelioma.The Cochrane database of systematic reviews · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alfredo TartaroneDepartment of Onco-Hematology, Unit of Medical Oncology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy. tarta1@virgilio.it.ORCID http://orcid.org/0000-0002-0859-7847
Rosa LeroseHospital Pharmacy, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy.
Michele AietaDepartment of Onco-Hematology, Unit of Medical Oncology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy.
Centro di Riferimento Oncologico della Basilicata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

Indexed as

ImmunotherapyAntineoplastic AgentsClinical Trials as TopicCombined Modality TherapyCTLA-4 AntigenHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorAntineoplastic AgentsCTLA-4 AntigenCTLA4 protein, humanPDCD1LG2 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorCAR T cell therapyImmune checkpoint inhibitorsImmunotherapyMalignant pleural mesothelioma

Identifiers

PMID29845408
OpenAlexW2805522985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.